Congenital Long QT Syndrome

Comprehensive Clinical Guide: Congenital Long QT Syndrome (LQTS)

1. Introduction and Overview

Congenital Long QT Syndrome (LQTS) is a complex, genetically heterogeneous cardiac channelopathy characterized by a prolongation of the ventricular repolarization phase, manifesting as a prolonged QT interval on the surface electrocardiogram (ECG). This electrical instability predisposes affected individuals to malignant ventricular arrhythmias, most notably Torsades de Pointes (TdP), which can degenerate into ventricular fibrillation, leading to syncope, seizure-like activity, or sudden cardiac death (SCD).

As an expert clinical entity, LQTS represents a classic example of the intersection between molecular genetics and clinical cardiology. While the prevalence is estimated at approximately 1 in 2,000 to 1 in 2,500 individuals, many cases remain undiagnosed due to incomplete penetrance and variable expressivity. This guide serves as an authoritative resource for clinicians, residents, and medical professionals managing patients with suspected or confirmed LQTS.

2. Technical Specifications and Pathophysiology

The Molecular Basis of Repolarization

The cardiac action potential is defined by the coordinated movement of ions across the sarcolemma. The QT interval on an ECG represents the duration of ventricular depolarization and repolarization. In LQTS, mutations in genes encoding cardiac ion channels (potassium, sodium, or calcium) disrupt the repolarization process.

Key Genetic Subtypes

The majority of LQTS cases are attributed to mutations in three primary genes:

Pathophysiological Mechanism: The "Afterdepolarization" Theory

The prolongation of the action potential duration (APD) creates an environment conducive to Early Afterdepolarizations (EADs). EADs occur when the membrane potential is delayed during the plateau phase, allowing for the reactivation of L-type calcium channels. These EADs serve as "triggers" for polymorphic ventricular tachycardia. When coupled with increased dispersion of repolarization (the substrate), the re-entrant circuits are easily initiated, leading to the characteristic "twisting" morphology of Torsades de Pointes.

3. Clinical Indications and Diagnostic Criteria

Standard Presentation

Clinical presentation varies significantly based on age, sex, and genotype. Common clinical indicators include:
* Syncope: Often triggered by physical exertion (LQT1), auditory stimuli such as alarms (LQT2), or occurring during sleep/rest (LQT3).
* Seizure-like activity: Frequently misdiagnosed as epilepsy. Any patient with "refractory epilepsy" should undergo a baseline ECG.
* Sudden Cardiac Arrest (SCA): Occasionally the first clinical manifestation.
* Family History: A history of unexplained drowning, sudden infant death syndrome (SIDS), or unexplained accidents in young family members.

The Schwartz Score (Diagnostic Criteria)

To standardize diagnosis, the Schwartz criteria are utilized to calculate the probability of LQTS.

• Interpretation: $\ge$ 3.5 points = High probability; 2–3 points = Intermediate; $\le$ 1 point = Low.

4. Differential Diagnosis and Diagnostic Testing

Differential Diagnosis

Clinicians must distinguish LQTS from other conditions that mimic its electrical phenotype:
1. Acquired Long QT Syndrome: Drug-induced (e.g., antiarrhythmics, macrolides, SSRIs) or electrolyte disturbances (hypokalemia, hypomagnesemia).
2. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT): Normal resting ECG but exercise-induced arrhythmias.
3. Brugada Syndrome: ST-segment elevation in V1-V3.
4. Short QT Syndrome: High risk of AFib and SCD.

Diagnostic Testing Protocol

• Resting 12-lead ECG: The cornerstone of diagnosis. Always correct for heart rate using Bazett’s formula ($QTc = QT / \sqrt{RR}$).
• Exercise Stress Test: Essential to evaluate the QTc response to sympathetic stimulation. In LQT1, the QTc often fails to shorten or paradoxically lengthens during recovery.
• Holter Monitoring: Useful for identifying T-wave alternans or nocturnal arrhythmias.
• Genetic Testing: Recommended for all patients with a high clinical suspicion to confirm the diagnosis, guide family screening, and tailor therapy.

5. Management, Risks, and Contraindications

Therapeutic Strategy

Management is risk-stratified based on the patient’s history and genotype.

1. Lifestyle Modifications:
   • Avoidance of competitive sports (especially in LQT1).
   • Avoidance of QT-prolonging medications (consult the CredibleMeds database).
   • Aggressive treatment of fever in children.
2. Pharmacological Intervention:
   • Beta-blockers: The gold standard for LQT1 and LQT2. Propranolol and nadolol are preferred due to their higher efficacy in suppressing sympathetic surges.
3. Surgical/Procedural Intervention:
   • Left Cardiac Sympathetic Denervation (LCSD): Used for patients who remain symptomatic despite beta-blocker therapy or who cannot tolerate beta-blockers.
   • ICD Implantation: Reserved for patients who have survived cardiac arrest or have recurrent syncope despite maximal medical therapy.

Contraindications and Risks

• Contraindicated Drugs: Class IA and III antiarrhythmics are strictly contraindicated. Many common antibiotics (e.g., Azithromycin) and anti-emetics (e.g., Ondansetron) must be used with extreme caution or avoided.
• Electrolyte Imbalance: Hypokalemia must be corrected immediately, as it exacerbates repolarization abnormalities.

6. Long-term Prognosis

With early diagnosis and appropriate management (beta-blockers and lifestyle modification), the prognosis for most LQTS patients is excellent. The risk of sudden death is significantly reduced. However, high-risk patients—defined by a history of cardiac arrest, QTc $>500$ ms, or specific genotypes (e.g., LQT3 or compound mutations)—require lifelong monitoring and aggressive management.

7. Frequently Asked Questions (FAQ)

1. Is LQTS always genetic?
Yes, by definition, Congenital LQTS is inherited. However, acquired LQTS exists due to external triggers.

2. Can I exercise if I have LQTS?
Low-intensity, non-competitive exercise is generally safe, but competitive sports are usually contraindicated for LQT1 patients. Consult a specialist for a personalized exercise plan.

3. Does everyone with the mutation get symptoms?
No. LQTS exhibits "incomplete penetrance," meaning some individuals with the genetic mutation may have a normal QTc and no symptoms, yet they can still pass the gene to offspring.

4. Why is the QT interval measured differently?
The QT interval varies with heart rate. The Bazett formula is the standard, though the Fridericia formula is sometimes preferred at very high or low heart rates.

5. What is the biggest danger of LQTS?
The development of Torsades de Pointes, a specific form of ventricular tachycardia that can lead to sudden cardiac death.

6. Are there specific antibiotics I should avoid?
Yes, many macrolides and fluoroquinolones prolong the QT interval. Always check the CredibleMeds database before starting any new medication.

7. Can a normal ECG rule out LQTS?
No. Because of variable expressivity, a person with a normal resting ECG may still carry the genetic mutation and be at risk.

8. Should family members be tested?
Yes, "cascade screening" is mandatory. Once a mutation is identified in a proband, all first-degree relatives should undergo genetic testing and ECG screening.

9. How effective are beta-blockers?
They are highly effective at preventing symptoms in the majority of patients, especially those with LQT1 and LQT2.

10. What is the role of an ICD in children?
ICDs are life-saving but carry long-term risks (infections, lead failure, inappropriate shocks). They are reserved for the highest-risk patients where other therapies have failed.

8. Clinical Conclusion

Congenital Long QT Syndrome remains a major focus of clinical electrophysiology. Through the diligent use of the Schwartz score, genetic testing, and adherence to evidence-based beta-blocker therapy, clinicians can effectively prevent sudden cardiac death. Awareness of the genotype-phenotype correlation is essential for modern risk stratification and long-term patient survival.

Disclaimer: This guide is intended for educational purposes for healthcare professionals and does not replace institutional clinical protocols or direct patient consultation.